Trial finds drug reteplase may be another option for stroke thrombolysis
UC expert comments on study to TCT MD
The University of Cincinnati's Pooja Khatri commented to TCTMD on the RAISE trial that found drug reteplase may be a safe and effective option to treat acute ischemic stroke.
Like drugs tenecteplase and alteplase, reteplase is a clot-busting medication that was administered to patients within 4.5 hours of stroke onset during the trial. The drug was found to lead to a higher rate of excellent functional outcome compared with standard alteplase with no significant increase in symptomatic intracranial hemorrhage, other bleeding outcomes or death.
The trial “raises the possibility of another intravenous thrombolytic drug that we could use to treat acute stroke patients,” said Khatri, MD, professor, vice chair of research and division chief in the Department of Neurology & Rehabilitation Medicine at UC's College of Medicine and associate director of the UC Gardner Neuroscience Institute, noting that this is the first phase III trial to address the topic.
“It opens some doors, but we need more data to know if this is going to have a role in our armamentarium as part of our standard of care in the long run,” Khatri added.
Featured photo at top of illustration of brain with stroke symptoms. Photo/PeterSchreiber.media/iStock.
Related Stories
CCM welcomes new film and media scoring faculty member J.R. Paredes
May 20, 2026
UC College-Conservatory of Music Dean Pete Jutras has announced the appointment of J.R. Paredes as CCM's new Assistant Professor of Film and Media Scoring. His faculty appointment officially begins on Aug. 15, 2026. Paredes is a composer, music producer and audio post-production specialist whose work spans film, television and commercial music. His credits include original scores for feature films and series distributed on platforms such as Apple TV+ and Prime Video, as well as extensive work in sound design and mixing for film and media.
6 ways starting a GLP-1 medication could affect your emotions
May 20, 2026
When patients first start taking a glucagon-like peptide-1 (GLP-1) medication, they probably expect to feel full. But they might not anticipate how it can influence their emotions. The medications act on the stomach and the brain, said Malti Vij, MD, a University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine and a diplomate of the American Board of Obesity Medicine.